• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjects

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    Erlotinib in combination with pemetrexed for patients with advanced non-small-cell lung cancer (NSCLC): a phase I dose-finding study.

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Authors
    Ranson, Malcolm R
    Reck, M
    Anthoney, A
    Hanauske, A-R
    Dean, Emma J
    Melezinek, I
    Klingelschmitt, G
    Kletzl, H
    Blatter, J
    Twelves, C
    Affiliation
    Department of Medical Oncology, University of Manchester, Christie Hospital, Manchester, UK.
    Issue Date
    2010-05-05
    
    Metadata
    Show full item record
    Abstract
    BACKGROUND: Erlotinib and pemetrexed are approved single agents for second-line treatment of non-small-cell lung cancer (NSCLC) and, in combination, have shown synergistic antitumor activity in NSCLC cell lines. We investigated the safety, pharmacokinetics and preliminary efficacy of combined erlotinib-pemetrexed in patients with refractory advanced NSCLC. PATIENTS AND METHODS: A nonrandomized, open-label, phase IB study was performed in patients with advanced NSCLC whose disease had progressed on or following first-line chemotherapy with a platinum-containing regimen or for whom the erlotinib-pemetrexed combination was considered appropriate. Patients received i.v. pemetrexed 500-700 mg/m(2) every 3 weeks and oral erlotinib 100-150 mg/day. RESULTS: Twenty patients were recruited. The most common adverse events (AEs) were rash, diarrhea and fatigue. Serious AEs occurred in eight patients (three treatment related) and there were eight deaths (none treatment related). Dose-limiting toxic effects were not experienced up to erlotinib 150 mg/day plus pemetrexed 600 mg/m(2). Concurrent administration did not affect pharmacokinetic parameters. Two patients achieved partial responses and nine had stable disease. CONCLUSIONS: Erlotinib-pemetrexed combination is well tolerated at doses equal to the licensed single-agent doses (150 mg/day and 500 mg/m(2), respectively). The good tolerability profile and promising efficacy indicate that this combination warrants further investigation for patients with advanced NSCLC.
    Citation
    Erlotinib in combination with pemetrexed for patients with advanced non-small-cell lung cancer (NSCLC): a phase I dose-finding study. 2010: Ann Oncol
    Journal
    Annals of Oncology
    URI
    http://hdl.handle.net/10541/109036
    DOI
    10.1093/annonc/mdq246
    PubMed ID
    20444843
    Type
    Article
    Language
    en
    ISSN
    1569-8041
    ae974a485f413a2113503eed53cd6c53
    10.1093/annonc/mdq246
    Scopus Count
    Collections
    All Christie Publications

    entitlement

    Related articles

    • Phase II study of pemetrexed plus intermittent erlotinib combination therapy for pretreated advanced non-squamous non-small cell lung cancer with documentation of epidermal growth factor receptor mutation status.
    • Authors: Minami S, Kijima T, Hamaguchi M, Nakatani T, Koba T, Takahashi R, Takeuchi Y, Kida H, Nagatomo I, Yamamoto S, Tachibana I, Komuta K, Kawase I
    • Issue date: 2013 Nov
    • Combination chemotherapy with intermittent erlotinib and pemetrexed for pretreated patients with advanced non-small cell lung cancer: a phase I dose-finding study.
    • Authors: Minami S, Kijima T, Takahashi R, Kida H, Nakatani T, Hamaguchi M, Takeuchi Y, Nagatomo I, Yamamoto S, Tachibana I, Komuta K, Kawase I
    • Issue date: 2012 Jul 18
    • Everolimus and erlotinib as second- or third-line therapy in patients with advanced non-small-cell lung cancer.
    • Authors: Papadimitrakopoulou VA, Soria JC, Jappe A, Jehl V, Klimovsky J, Johnson BE
    • Issue date: 2012 Oct
    • Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer.
    • Authors: Smit EF, Burgers SA, Biesma B, Smit HJ, Eppinga P, Dingemans AM, Joerger M, Schellens JH, Vincent A, van Zandwijk N, Groen HJ
    • Issue date: 2009 Apr 20
    • Sunitinib plus erlotinib for the treatment of advanced/metastatic non-small-cell lung cancer: a lead-in study.
    • Authors: Blumenschein GR Jr, Ciuleanu T, Robert F, Groen HJ, Usari T, Ruiz-Garcia A, Tye L, Chao RC, Juhasz E
    • Issue date: 2012 Sep
    DSpace software (copyright © 2002 - 2019)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.